Tirzepatide: what the trials tested, and what they did not
| Product | Tested in a trial? | Average weight loss | FDA review |
|---|---|---|---|
| Zepbound shot (tirzepatide 15 mg) | Yes: SURMOUNT-1, 72 weeks | 20.9% vs 3.1% on placebo; 56.7% lost at least 20% | FDA-approved for weight loss |
| Tirzepatide vs. semaglutide, head to head | Yes: SURMOUNT-5, 72 weeks | Tirzepatide 20.2% vs semaglutide 13.7% (treatment-regimen estimand) | Both brands FDA-approved |
| Compounded tirzepatide shot | No | No trial result exists | Not FDA-approved; not reviewed for safety, effectiveness or quality before it is sold |
| Compounded tirzepatide tablet | No | No trial result exists; no tirzepatide tablet is FDA-approved | Not FDA-approved; not reviewed before it is sold |
SURMOUNT-1 figures from the Zepbound prescribing information (Table 2, all randomized patients); SURMOUNT-5 from the NEJM report, as listed in our trial results table. FDA wording from its page on concerns with unapproved GLP-1 drugs used for weight loss.
Why the trial result belongs to Zepbound
SURMOUNT-1 tested Eli Lilly's tirzepatide, approved as Zepbound in November 2023. Compounded tirzepatide is prepared by a pharmacy for each prescription and is not FDA-approved; the FDA does not review it for safety, effectiveness or quality before it is sold. So no study can say how well a given compounded vial works. It can match the trial only by delivering the same molecule at the same dose.
The dose schedule behind the trial number
The Zepbound label starts at 2.5 mg a week for 4 weeks and raises the dose in 2.5 mg steps, at least 4 weeks apart, to a maintenance dose of 5, 10 or 15 mg. Reaching 15 mg takes at least 20 weeks. The 20.9% average was measured on 15 mg at week 72, so a few weeks on a starting dose say little about where you will end up.
With compounded vials, the dose you get depends on the vial strength and the units you draw. Check the mg per mL on each new vial and ask the clinician to write your dose in units for that vial.
Compounded tirzepatide tablets
No tirzepatide tablet has been approved by the FDA; Zepbound and Mounjaro are weekly injections, and their trials tested the injection. 3 programs we compare list a compounded tirzepatide tablet or oral form. If you choose one, ask the clinician how its dose compares with the injection, because how much tirzepatide the body absorbs from it is not established.
The lowest compounded tirzepatide prices among the programs we compare on Nov 12, 2026: $96 a month on yourEra's 12-month plan ($1,152 billed upfront); $99.99 a month on Maximus' 12-month plan (paid up front; $199.99 on 2 months); $109 a month at SnagRx, month to month (pre-Black Friday sale price, was $349, locked in; the page counts down to a price increase).







